M.D., Ph.D., Clinical Research and Medical Practice Liaison

Contact Info

Aloke Mandal, M.D., Ph. D. provides clinical subject matter expertise for the Hardesty Healthcare Solutions practice of Hardesty, LLC and leads our Medical & Physician Consulting Practice initiative. Dr. Mandal was a nationally renowned academic transplant surgeon, general surgeon, and surgical oncologist. In addition to publishing multiple research papers on the biomedical sciences and healthcare delivery sciences, Dr. Mandal was part of Johns Hopkins Hospital team that pioneered laparoscopic live donor nephrectomy and thus appeared on the cover of U.S. News & World Reports.

He has been a medical director at Fortune 100 health plan and healthcare services companies. His primary focus has been on developing innovative value-based insurance design that have improved clinical outcomes, reduced mortality, generated cost-efficiencies, and improved physician reimbursement. In fact, his 2017 American Journal of Managed Care article on alternative payment models in Medicare Advantage often is cited in Congress and among healthcare industry leaders whenever discussing Medicare payment reform. He thus provides a unique blend of clinical and healthcare business acumen required for developing population health management and value-based contracting.

Since joining Hardesty, he has provided project management support for a blockchain company involved in electronic healthcare records, assisted behavioral health practices to in value-based insurance design, developed a strategic relationship for lower extremity joint replacements in ambulatory surgery centers as a bundled care payment initiative, and acted as a liaison between a health plan and pediatric accountable care organization to reduce hospital-based utilization for ambulatory care sensitive conditions and low-value care that actually can harm patients.

As a team player, Aloke also provides clinical input and clinical research oversight for our other partners who are working with private equity, investment banking, venture capital, medical device, biopharmaceutical, and life sciences firms that are involved with emerging biomedical technologies and healthcare practices.